Skip to content

Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation

Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03159923
Acronym
TRAP
Enrollment
200
Registered
2017-05-19
Start date
2017-01-19
Completion date
2023-03-23
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Remodeling, Cardiac, Tricuspid Regurgitation

Brief summary

The aim of this study is to improve the definition of the two main types of secondary tricuspid regurgitation.

Interventions

OTHERModerate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.

Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any patients ≥ 18 years old, with moderate to severe tricuspid regurgitation (≥ 2/4), agreeing to participate ; * The patients included can be ambulatory patients or stabilized hospitalised patients (meaning patient clinicaly stable, not decompensated, and whose normovolemia has been checked). * Non opposition of the patient

Exclusion criteria

* Patient whose accoustic window is judged by the operator as incompatible with a precise evaluation of the tricuspid regurgitation or anatomy of the right cavity ; * TR \< grade 2 ; * TR secondary to primary pulmonary hypertension or congenital cardiopathy ; * Primary tricuspid regurgitation (due to rheumatic heart disease, medication - included benfluorex, due to endocarditis, valvular prolapse, carcinoid syndrom or a cardiac stimulation lead …) ; * Significant left heart valvulopathy (Mitral regurgitation \> grade 2, Aortic insufficiency \> grade 2, Mitral stenosis \< 2 cm², Aortic stenosis \< 1.5 cm²). A valvulopathy sucessfully operated isn't considered as an

Design outcomes

Primary

MeasureTime frame
Composite criteria : cardiovascular death or unscheduled hospitalizations due to cardiovascular event.through study completion, an average of 1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026